-
1.发明公开
公开(公告)号：EP3681535A1
公开(公告)日：2020-07-22
申请号：EP18779538.0
申请日：2018-09-12
发明人： LEWIS, Katherine E. , PERNA, Serena , CARLETON, Michael , XU, Ke , PHILLIPS, Penny , PANDYA, Dimple , WONG, Brian , HAMBLETON, Julie , SIKORSKI, Robert , MASTELLER, Emma , HESTIR, Kevin , BELLOVIN, David , POWERS, Janine , LEE, Ernestine
IPC分类号： A61K39/395 , A61K45/06 , C07K16/28 , A61K39/00
-
公开(公告)号：EP3212670A1
公开(公告)日：2017-09-06
申请号：EP15798264.6
申请日：2015-10-28
发明人： WONG, Brian , HAMBLETON, Julie , SIKORSKI, Robert , MASTELLER, Emma , HESTIR, Kevin , BELLOVIN, David , LEWIS, Katherine E.
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
CPC分类号： C07K16/2866 , A61K2039/505 , A61K2039/507 , A61K2039/54 , A61K2039/545 , C07K16/2803 , C07K16/2818 , C07K16/3046 , C07K16/3069 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
摘要： Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
摘要翻译： 提供了用结合集落刺激因子1受体（CSF1R）与PD-1 / PD-L1抑制剂组合的抗体治疗癌症的方法。
-
公开(公告)号：EP3835323A1
公开(公告)日：2021-06-16
申请号：EP20207287.2
申请日：2015-10-28
发明人： WONG, Brian , HAMBLETON, Julie , SIKORSKI, Robert , MASTELLER, Emma , HESTIR, Kevin , BELLOVIN, David , LEWIS, Katherine E.
IPC分类号： C07K16/28 , A61K39/395 , A61P35/00
摘要： Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
-
4.发明公开FAM150A, FAM150B, AND FAM150 ANTAGONISTS AND USES THEREOF 审中-公开FAM150A，FAM150B- UND FAM150-ANTAGONISTEN UND VERWENDUNGEN DAVON
公开(公告)号：EP2970495A1
公开(公告)日：2016-01-20
申请号：EP14773609.4
申请日：2014-03-07
IPC分类号： C07K16/28
CPC分类号： C07K16/18 , A61K38/1703 , A61K38/45 , A61K39/3955 , A61K45/06 , C07K16/00 , C07K16/40 , C07K2319/30 , C12Y207/10001 , G01N33/573 , G01N2333/4706 , G01N2333/912 , G01N2440/14 , G01N2500/02 , G01N2500/04 , G01N2500/10
摘要： Methods of identifying and using FAM150A agents, FAM150B agents, and FAM150 antagonists are provided. Methods of identifying and using L TK agonists (including L TK agonist antibodies, FAM150A agents, and FAM150B agents) and FAM150 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer, methods of treating immune disorders such as autoimmune diseases, and methods of treating neurodegenerative diseases.
摘要翻译： 提供了鉴定和使用FAM150A试剂，FAM150B试剂和FAM150拮抗剂的方法。 提供了鉴定和使用LTK激动剂（包括LTK激动剂抗体，FAM150A试剂和FAM150B试剂）和FAM150拮抗剂的方法。 这些方法包括但不限于治疗癌症的方法，治疗免疫疾病如自身免疫性疾病的方法和治疗神经退行性疾病的方法。
-
公开(公告)号：EP2780033A1
公开(公告)日：2014-09-24
申请号：EP12849489.5
申请日：2012-11-13
发明人： HARDING, Thomas , PALENCIA, Servando , LONG, Li , HESTIR, Kevin
CPC分类号： A61K38/179 , A61K39/395 , A61K45/00 , A61K45/06 , C07K14/71 , C07K2319/30 , C12Q1/6813 , C12Q1/686 , G01N33/5005 , A61K2300/00
摘要： Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
摘要翻译： 提供了治疗包含FGFR1基因扩增的癌症的方法。 在一些实施方案中，所述方法包括施用成纤维细胞生长因子受体1（FGFR1）胞外结构域（ECD）和/或FGFR1 ECD融合分子。 在一些实施方案中，所述方法包括与至少一种另外的治疗剂组合施用成纤维细胞生长因子受体1（FGFR1）胞外结构域（ECD）和/或FGFR1 ECD融合分子。
-
公开(公告)号：EP1778842B8
公开(公告)日：2012-03-21
申请号：EP05791762.7
申请日：2005-07-21
发明人： BEHRENS, Dirk , BOSCH, Elizabeth , DOBERSTEIN, Steven , HALENBECK, Robert, Forgan , HESTIR, Kevin , HUANG, Min, Mei , LEE, Ernestine , LIN, Haishan , LINNEMANN, Thomas Five Prime Therapeutics, Inc. , MARSHALL, Shannon , WONG, Justin, G., P. , WU, Ge , ZHOU, Aileen , LEO, Cindy , WILLIAMS, Lewis, T.
IPC分类号： C07K14/53
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
-
7.发明授权
公开(公告)号：EP1910542B1
公开(公告)日：2009-12-02
申请号：EP06800260.9
申请日：2006-07-24
发明人： WILLIAMS, Lewis, T. , BOSCH, Elizabeth , DOBERSTEIN, Stephen , HESTIR, Kevin , HOLLENBAUGH, Diane , LEE, Ernestine , QIN, Minmin , SADRA, Ali , WONG, Justin , WU, Ge , ZHANG, Hongbing
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
-
公开(公告)号：EP1778842A2
公开(公告)日：2007-05-02
申请号：EP05791762.7
申请日：2005-07-21
发明人： BEHRENS, Dirk , BOSCH, Elizabeth , DOBERTEIN, Steven , HALENBECK, Robert, Forgan , HESTIR, Kevin , HUANG, Min, Mei , LEE, Ernestine , LIN, Haishan , LINNEMANN, Thomas , MARSHALL, Shannon , WONG, Justin, G., P. , WU, Ge , ZHOU, Aileen , LEO, Cindy , WILLIAMS, Lewis, T.
IPC分类号： C12N15/27
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
-
9.发明授权
公开(公告)号：EP2780033B1
公开(公告)日：2019-05-08
申请号：EP12849489.5
申请日：2012-11-13
发明人： HARDING, Thomas , PALENCIA, Servando , LONG, Li , HESTIR, Kevin
-
公开(公告)号：EP1778842B1
公开(公告)日：2012-01-11
申请号：EP05791762.7
申请日：2005-07-21
发明人： BEHRENS, Dirk , BOSCH, Elizabeth , DOBERSTEIN, Steven , HALENBECK, Robert, Forgan , HESTIR, Kevin , HUANG, Min, Mei , LEE, Ernestine , LIN, Haishan , LINNEMANN, Thomas Five Prime Therapeutics, Inc. , MARSHALL, Shannon , WONG, Justin, G., P. , WU, Ge , ZHOU, Aileen , LEO, Cindy , WILLIAMS, Lewis, T.
IPC分类号： C07K14/53
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.024 秒)
